vt3989
vivace therapeutics
['vt3989', 'mesothelioma']
the #oncoalerttoptweet day 5 of #aacr23 tweet by 1 st -in-class, fih phase i trial of vt3989 (yap/tead inhibitor) by dr. timothy "yap". impressive response in patients with malignant mesothelioma with nf2 mutations nf2 mutation (inactivation) is 
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨